On December 15, the US Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer. 

For more information read the FDA announcement, Astellas Pharma announcement, and Merck announcement.

Posted 12/18/2023